Intercept Pharmaceuticals (NASDAQ:ICPT) Given New $28.00 Price Target at Raymond James

Posted by Defense World Staff on Mar 6th, 2023

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its price objective hoisted by Raymond James from $26.00 to $28.00 in a research note issued to investors on Sunday morning, The Fly reports.

A number of other analysts have also commented on the stock. SVB Leerink lifted their price target on shares of Intercept Pharmaceuticals from $17.00 to $18.00 and gave the stock a market perform rating in a research note on Friday. Needham & Company LLC boosted their target price on shares of Intercept Pharmaceuticals from $22.00 to $26.00 and gave the company a buy rating in a research note on Friday. SVB Securities increased their price target on Intercept Pharmaceuticals from $17.00 to $18.00 in a report on Friday. Royal Bank of Canada lifted their price objective on Intercept Pharmaceuticals from $17.00 to $19.00 and gave the stock a sector perform rating in a report on Friday. Finally, HC Wainwright lowered their target price on Intercept Pharmaceuticals from $16.00 to $14.00 and set a neutral rating on the stock in a report on Wednesday, November 16th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $26.00.

Intercept Pharmaceuticals Trading Up 0.5 %

Intercept Pharmaceuticals stock opened at $20.68 on Friday. Intercept Pharmaceuticals has a one year low of $10.81 and a one year high of $21.86. The business’s fifty day moving average is $17.40 and its 200 day moving average is $16.05. The company has a debt-to-equity ratio of 2.40, a current ratio of 2.35 and a quick ratio of 2.35. The stock has a market capitalization of $861.74 million, a PE ratio of 3.20 and a beta of 1.29.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ICPT. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Intercept Pharmaceuticals by 14.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,453 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 688 shares in the last quarter. Delphia USA Inc. raised its position in shares of Intercept Pharmaceuticals by 4.6% during the 2nd quarter. Delphia USA Inc. now owns 17,109 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 756 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Intercept Pharmaceuticals by 0.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 157,510 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 795 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Intercept Pharmaceuticals by 0.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 164,210 shares of the biopharmaceutical company’s stock valued at $2,672,000 after buying an additional 825 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Intercept Pharmaceuticals by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 29,409 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 1,210 shares during the period. Institutional investors own 81.09% of the company’s stock.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.